United Therapeutics Corp (NASDAQ: UTHR) is 58.52% higher on its value in year-to-date trading and has touched a low of $208.62 and a high of $343.98 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The UTHR stock was last observed hovering at around $320.99 in the last trading session, with the day’s gains setting it 27.59%.
Currently trading at $348.58, the stock is 6.05% and 9.79% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.97 million and changing 8.60% at the moment leaves the stock 35.97% off its SMA200. UTHR registered 52.81% gain for a year compared to 6-month gain of 62.33%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 5.90% loss in the last 1 month and extending the period to 3 months gives it a 27.10%, and is 4.43% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.93% over the week and 3.11% over the month.
United Therapeutics Corp (UTHR) has around 1168 employees, a market worth around $15.51B and $2.62B in sales. Current P/E ratio is 16.01 and Fwd P/E is 12.37. Profit margin for the company is 40.87%. Distance from 52-week low is 67.08% and 1.34% from its 52-week high. The company has generated returns on investments over the last 12 months (18.45%).
The EPS is expected to grow by 25.18% this year.
United Therapeutics Corp (UTHR) Top Institutional Holders
834.0 institutions hold shares in United Therapeutics Corp (UTHR), with institutional investors hold 108.05% of the company’s shares. The shares outstanding are 47.04M, and float is at 43.67M with Short Float at 9.43%. Institutions hold 106.05% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 5.57 million shares valued at $$1.28 billion. The investor’s holdings represent 11.8458 of the UTHR Shares outstanding. As of 2024-03-31, the second largest holder is VANGUARD GROUP INC with 4.68 million shares valued at $$1.08 billion to account for 9.964 of the shares outstanding. The other top investors are WELLINGTON MANAGEMENT GROUP LLP which holds 3.41 million shares representing 7.2601 and valued at over $$783.86 million, while AVORO CAPITAL ADVISORS LLC holds 6.0827 of the shares totaling 2.86 million with a market value of $$656.74 million.
United Therapeutics Corp (UTHR) Insider Activity
The most recent transaction is an insider sale by ROTHBLATT MARTINE A,the company’sChairperson & CEO. SEC filings show that ROTHBLATT MARTINE A sold 3,600 shares of the company’s common stock on Aug 15 ’24 at a price of $323.32 per share for a total of $1.16 million. Following the sale, the insider now owns 130.0 shares.
United Therapeutics Corp disclosed in a document filed with the SEC on Aug 16 ’24 that ROTHBLATT MARTINE A (Chairperson & CEO) sold a total of 3,600 shares of the company’s common stock. The trade occurred on Aug 16 ’24 and was made at $320.68 per share for $1.15 million. Following the transaction, the insider now directly holds 130.0 shares of the UTHR stock.
Still, SEC filings show that on Aug 19 ’24, JAMES EDGEMOND (Officer) Proposed Sale 7,828 shares at an average price of $329.02 for $2.58 million. The insider now directly holds shares of United Therapeutics Corp (UTHR).
